Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anadys/Novartis Hepatitis C Candidate Could Be Back In The Clinic By Year End

This article was originally published in The Pink Sheet Daily

Executive Summary

A 13-week preclinical toxicology study of ANA975 aims to explain dose dependence and immune stimulation concerns that led to FDA’s clinical hold for the toll-like receptor agonist.
Advertisement

Related Content

Vertex And Schering Hold Hep C Lead, But Others Look To Deal Themselves In
Vertex And Schering Hold Hep C Lead, But Others Look To Deal Themselves In
Anadys, Novartis Pull Plug On Toll-Like Receptor Candidate
Anadys, Novartis Pull Plug On Toll-Like Receptor Candidate
Coley Seeks HCV Partner For Actilon
Coley Seeks HCV Partner For Actilon
Merck To Incorporate Idera’s TLR Agonists Into Vaccine Program

Topics

Advertisement
UsernamePublicRestriction

Register

PS065672

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel